多囊卵巢综合征患者2型糖尿病、代谢功能障碍相关脂肪性肝病及心血管疾病风险
基于英国生物银行数据,比较1008例多囊卵巢综合征(PCOS)女性与5017例年龄及体重指数匹配对照的结局。PCOS患者2型糖尿病及全因心血管疾病发生风险更高,肝脏MRI显示肝脂肪变及纤维炎症更重,癌症与痴呆无组间差异;心血管风险在非高雄激素型更高,肝脂肪变在高雄激素型更明显。
要点
- PCOS患者2型糖尿病风险升高(HR 1.47,95%CI 1.11-1.95),全因心血管疾病风险升高(HR 1.76,95%CI 1.35-2.30)。
- PCOS患者肝脂肪变(PDFF>5.5%)比例35.9% vs 对照23.9%(P=.02),纤维炎症指标校正T1更高(721.4 vs 701.5 ms,P<.01)。
- 非高雄激素型PCOS全因心血管疾病风险升高(HR 1.82,95%CI 1.29-2.56),高雄激素型PCOS肝脂肪变及纤维炎症更明显。
核心结论
- PCOS患者的心脏代谢疾病风险可能升高,且呈现疾病表型特异性模式。
研究设计与样本
- 基于英国生物银行数据的比较研究,纳入1008例PCOS女性(经诊断编码、自我报告诊断或高雄激素血症合并月经稀发/闭经的临床/生化特征定义)与5017例按年龄和体重指数匹配的对照(5:1),中位年龄61岁,体重指数28.4 kg/m²。
主要发现
- 校正Cox比例风险模型显示,PCOS组2型糖尿病发生风险高于对照(HR 1.47;95%CI 1.11-1.95),全因心血管疾病风险亦高于对照(HR 1.76;95%CI 1.35-2.30);癌症与痴呆无组间差异。
- 肝脏MRI显示PCOS组肝脂肪变(质子密度脂肪分数>5.5%)比例高于对照(35.9% vs 23.9%;P=.02),纤维炎症指标校正T1高于对照(721.4 vs 701.5 ms;P<.01);心脏(双心室/心房结构与功能)及脑(灰质与白质体积)影像无组间差异。
- 非高雄激素型PCOS组全因心血管疾病发生风险高于对照(HR 1.82;95%CI 1.29-2.56),高雄激素型PCOS组无此差异;高雄激素型PCOS组肝脂肪变比例高于非高雄激素型PCOS组及对照组(8.96% vs 6.04% vs 5.23%;P=.03),纤维炎症指标校正T1亦更高(776.3 vs 707.7 vs 701.9 ms;P<.01)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Polycystic ovary syndrome (PCOS) is associated with adverse clinical outcomes that may differ according to PCOS phenotype. METHODS: Using UK Biobank data, we compared the incidence of type 2 diabetes (T2D), metabolic dysfunction associated steatotic liver disease, cardiovascular disease (CVD), hormone-dependent cancers, and dementia between PCOS participants and age- and body mass index-matched controls. We also compared multiorgan (liver, cardiac, and brain) magnetic resonance imaging (MRI) data and examined the impact of PCOS phenotype (hyperandrogenic and normoandrogenic) on these outcomes. RESULTS: We included 1008 women with PCOS (defined by diagnostic codes, self-reported diagnoses, or clinical/biochemical features of hyperandrogenism and a/oligoCmenorrhoea) and 5017 matched controls (5:1 ratio); median age, 61 years, body mass index, 28.4 kg/m². Adjusted Cox proportional hazard modeling demonstrated PCOS participants had greater incident T2D [hazard ratio (HR) 1.47; 95% confidence interval (CI), 1.11-1.95] and all-cause CVD (1.76; 1.35-2.30). No between-group differences existed for cancers or dementia. Liver MRI confirmed more PCOS participants had hepatic steatosis (proton density fat fraction >5.5%: 35.9 vs 23.9%; P = .02) and higher fibroinflammation (corrected T1 721.4 vs 701.5 ms; P = <.01) vs controls. No between-group difference existed for cardiac (biventricular/atrial structure and function) or brain (grey and white matter volumes) imaging. Normoandrogenic (but not hyperandrogenic) PCOS participants had greater incident all-cause CVD (1.82; 1.29-2.56) while hyperandrogenic (but not normoandrogenic) PCOS participants were more likely to have hepatic steatosis (8.96 vs 6.04 vs 5.23%; P = .03) with greater fibroinflammation (776.3 vs 707.7 vs 701.9 ms; P=<.01). CONCLUSION: Cardiometabolic disease may be increased in PCOS patients with a disease phenotype-specific pattern.
引用
- Henney AE, Gillespiec CS, Lai JYM, et al. Risk of Type 2 Diabetes, MASLD and Cardiovascular Disease in People Living With Polycystic Ovary Syndrome. J Clin Endocrinol Metab. 2025. PMID: 38986027. doi:10.1210/clinem/dgae481
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。